MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
40.18
+1.71 (4.45%)
At close: May 12, 2025, 4:00 PM
39.31
-0.87 (-2.17%)
After-hours: May 12, 2025, 7:11 PM EDT
MLTX Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for MLTX stock have an average target of 80.5, with a low estimate of 66 and a high estimate of 104. The average target predicts an increase of 100.35% from the current stock price of 40.18.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MLTX stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +64.26% | Apr 30, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $67 | Buy | Initiates | $67 | +66.75% | Mar 18, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $82 → $73 | Strong Buy | Maintains | $82 → $73 | +81.68% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +148.88% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Maintains $62 → $66 | Strong Buy | Maintains | $62 → $66 | +64.26% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
1.13B
from 553.54M
Increased by 103.42%
Revenue Next Year
n/a
from 1.13B
EPS This Year
-3.08
from -1.89
EPS Next Year
-3.80
from -3.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 192.1M | ||
| Avg | n/a | n/a | 101.1M | ||
| Low | n/a | n/a | 45.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.36 | -2.72 | -2.78 | ||
| Avg | -3.08 | -3.80 | -3.86 | ||
| Low | -3.26 | -4.93 | -4.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.